Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Shukui Qin, Shukui Qin, Stephen L Chan et al. · The Lancet · 2023
Cited by 737 works. doi:10.1016/s0140-6736(23)00961-3
Authors
- Shukui Qin
- Zhenggang Ren
- Xiaoyan Lin
- Yongdong Jin
- Yongdong Jin
- Yabing Guo
- Zhiqiang Meng
- Jun Liang
- Jianping Xiong
References
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
- Sorafenib in Advanced Hepatocellular Carcinoma
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth